// App-Quantinova.ai

: Long-Term Efficacy of Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis (AD): Results From an Open-Label Extension (OLE) Trial up to 4 years

Researchers

Presenter

  • Jacob P. Thyssen

Principal Investigators

  • Andrew Blauvelt

  • Benjamin Lockshin

  • Ryszard Galus

  • Charles Lynde

  • Jing Xiao

  • Noah A. Levit

  • Ainara Rodríguez Marco

  • Arsalan Shabbir

Medical Centers

  • Herlev Hospital, University of Copenhagen, Herlev, Denmark

  • Oregon Medical Research Center, Portland, OR, USA, Portland, OR

  • Georgetown University, Washington, DC

  • Medical University of Warsaw, Warsaw, Poland

  • University of Toronto, Markham, ON, Canada

  • Lynderm Research Inc., Markham, ON, Canada

  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY

  • Sanofi Genzyme, Madrid, Spain

Locations

  • United States

  • Canada

  • United Kingdom

  • Denmark

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

Disease

  • Atopic Dermatitis

Biomarkers

  • N/A

Drug/Treatment

  • Dupilumab

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • N/A

Study Id's

  • NCT01949311

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved